A detailed history of Advisor Group Holdings, Inc. transactions in Lumos Pharma, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 310 shares of LUMO stock, worth $1,221. This represents 0.0% of its overall portfolio holdings.

Number of Shares
310
Previous 154 101.3%
Holding current value
$1,221
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.19 - $3.04 $341 - $474
156 Added 101.3%
310 $0
Q1 2024

May 10, 2024

SELL
$2.64 - $3.22 $11,763 - $14,348
-4,456 Reduced 96.66%
154 $0
Q4 2023

Feb 12, 2024

SELL
$2.81 - $4.27 $8,548 - $12,989
-3,042 Reduced 39.75%
4,610 $14,000
Q3 2023

Nov 13, 2023

BUY
$2.63 - $3.49 $7,221 - $9,583
2,746 Added 55.97%
7,652 $25,000
Q2 2023

Aug 10, 2023

BUY
$3.01 - $4.38 $1,128 - $1,642
375 Added 8.28%
4,906 $16,000
Q1 2023

May 12, 2023

BUY
$3.16 - $4.0 $6,373 - $8,068
2,017 Added 80.23%
4,531 $14,000
Q4 2022

Feb 10, 2023

BUY
$3.05 - $9.52 $3,144 - $9,815
1,031 Added 69.52%
2,514 $9,000
Q3 2022

Nov 14, 2022

SELL
$7.35 - $9.05 $9,547 - $11,755
-1,299 Reduced 46.69%
1,483 $13,000
Q2 2022

Aug 10, 2022

SELL
$6.68 - $9.39 $3,780 - $5,314
-566 Reduced 16.91%
2,782 $22,000
Q1 2022

May 04, 2022

BUY
$6.58 - $10.09 $11,120 - $17,052
1,690 Added 101.93%
3,348 $32,000
Q3 2021

Nov 05, 2021

SELL
$7.36 - $11.36 $5,431 - $8,383
-738 Reduced 30.8%
1,658 $16,000
Q2 2021

Aug 02, 2021

BUY
$9.75 - $13.44 $11,563 - $15,939
1,186 Added 98.02%
2,396 $24,000
Q4 2020

Feb 10, 2021

SELL
$13.61 - $35.91 $26,131 - $68,947
-1,920 Reduced 61.34%
1,210 $42,000
Q3 2020

Nov 12, 2020

SELL
$13.25 - $16.5 $92 - $115
-7 Reduced 0.22%
3,130 $43,000
Q2 2020

Aug 14, 2020

BUY
$7.76 - $16.99 $256 - $560
33 Added 1.06%
3,137 $52,000
Q1 2020

May 18, 2020

BUY
$0.89 - $8.85 $2,762 - $27,470
3,104 New
3,104 $26,000

Others Institutions Holding LUMO

About LUMOS PHARMA, INC.


  • Ticker LUMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,396,070
  • Market Cap $33.1M
  • Description
  • Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...
More about LUMO
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.